Evelyn Partners Investment Management Services Ltd Has $327,000 Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Evelyn Partners Investment Management Services Ltd lifted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 375.8% in the second quarter, HoldingsChannel.com reports. The firm owned 609 shares of the company’s stock after acquiring an additional 481 shares during the period. Evelyn Partners Investment Management Services Ltd’s holdings in IDEXX Laboratories were worth $327,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the business. STF Management LP increased its holdings in IDEXX Laboratories by 1.3% in the 2nd quarter. STF Management LP now owns 1,240 shares of the company’s stock valued at $665,000 after buying an additional 16 shares during the period. Clearstead Trust LLC raised its position in IDEXX Laboratories by 1.1% in the second quarter. Clearstead Trust LLC now owns 1,515 shares of the company’s stock worth $813,000 after purchasing an additional 16 shares in the last quarter. Stratos Wealth Partners LTD. lifted its stake in IDEXX Laboratories by 1.7% during the second quarter. Stratos Wealth Partners LTD. now owns 1,051 shares of the company’s stock worth $564,000 after purchasing an additional 18 shares during the period. Red Spruce Capital LLC boosted its holdings in IDEXX Laboratories by 1.1% during the second quarter. Red Spruce Capital LLC now owns 1,701 shares of the company’s stock valued at $912,000 after purchasing an additional 19 shares in the last quarter. Finally, Huntington National Bank grew its stake in shares of IDEXX Laboratories by 0.5% in the 2nd quarter. Huntington National Bank now owns 3,651 shares of the company’s stock valued at $1,958,000 after purchasing an additional 19 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

IDXX opened at $725.91 on Friday. The company’s 50-day simple moving average is $656.12 and its two-hundred day simple moving average is $595.80. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $735.59. The stock has a market capitalization of $57.96 billion, a P/E ratio of 60.44, a P/E/G ratio of 4.06 and a beta of 1.62. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, November 3rd. The company reported $3.22 earnings per share for the quarter, beating analysts’ consensus estimates of $3.14 by $0.08. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The business had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same period in the previous year, the business earned $2.80 EPS. The company’s quarterly revenue was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. As a group, analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Analysts Set New Price Targets

IDXX has been the subject of several recent analyst reports. UBS Group increased their price objective on IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 4th. Leerink Partners set a $785.00 target price on shares of IDEXX Laboratories in a research report on Monday, November 3rd. Weiss Ratings restated a “hold (c+)” rating on shares of IDEXX Laboratories in a research report on Wednesday. JPMorgan Chase & Co. upped their price objective on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Finally, Morgan Stanley lifted their target price on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $730.50.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the business’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the completion of the sale, the executive vice president directly owned 21,149 shares in the company, valued at $14,874,937.66. The trade was a 30.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.